24 Jan 2017
CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry
Switzer Super Report
10 Oct 2016
Top commentator James Dunn from Switzer report rates CDY as a very interesting buy
Van Leeuwenhoeck Research
27 Jun 2016
14 Sep 2015
Cellmid Limited: Revenue stage biotech with strong pipeline
Baillieu Holst Research
24 Nov 2014
It’s rare for one company to own a whole new target this big
13 June 2014
Australian Life Sciences
30 May 2014
It's rare for a company to own a whole new target this big
First-in-Class mAb Oncology Program Will Rerate the Stock; Lots of Room to Grow for Advangen; New Target Price of 8.4c
Strong Investment Thesis Going Forward: Multiple Catalysts and Upside Opportunities - A Rare Find
Initiates coverage on Cellmid Limited; AUD $0.10 Target Price...
A pivotal year for Cellmid...
Looking to profit from large IP portfolio...
Targeting the early detection of cancer...